DXB 8.89% 49.0¢ dimerix limited

Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-49

  1. 1,982 Posts.
    lightbulb Created with Sketch. 434
    as OVF mentioned yesterday.... 10 patients study is completely fine for a rare disease

    and as DoctorBrad mentioned above.... results are better than Sparsentan ....

    either u purposely trying to spread misinformation or u clearly have no idea what u talking about ...

    in both cases.... it doesn't help ..

    how the market reacts no one knows .... but results are positive and I mean very positive
    Last edited by singhgu: 29/07/20
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.